Web Results

www.post-gazette.com/.../26/ignore-polls-Collier-Gene-Therapy/stories/202010260110

Advice regarding polling in the final week of a presidential race has long since calcified into one universal dictum – ignore the polls. Well, thanks...

www.nei.nih.gov/about/news-and-events/news/scientists-use-gene-therapy-and...

Gene replacement therapy has thus far worked principally in rare diseases that leave photoreceptors intact, such as Luxurna for Leber congenital amaurosis. Bionic eyes, such as the Argus II retinal prosthesis, require invasive surgery and wearable hardware.

www.statnews.com/2020/10/22/new-rare-disease-gene-therapy-startup-recruits...

A three-year-old gene therapy startup from Florida is relaunching Thursday with an infusion of health care investor cash and a chief executive officer recruited from Sarepta Therapeutics ...

www.goodnewsnetwork.org/gene-replacement-therapy-lets-blind-boy-see

The targeted gene therapy protocol, developed in the U.S., was recently green-lit for use in Canada, but with Sam’s sight failing, he and his mom, Sarah Banon, traveled to America last year to ...

www.thepharmaletter.com/listing/news/gene-therapy?tagid[]=45076

Astellas makes strong move into gene therapy with $3 billion acquisition. 03-12-2019. Astellas Pharma on Monday evening announced that it has entered into a definitive agreement to acquire… Astellas AT132 Audentes Therapeutics Biotechnology Cell and Gene Therapy Companies, mergers and acquisitions Gene therapy Japan USA

www.stltoday.com/business/germanys-bayer-to-buy-us-gene-therapy-specialist...

BERLIN (AP) — German health care company Bayer said Monday it is buying Asklepios BioPharmaceutical, a U.S.-based firm specializing in gene therapy, in a deal worth up to $4 billion.

www.biopharmadive.com/news/voyager-huntington-gene-therapy-clinical-hold/586920

The first gene therapy to launch in the U.S., Roche's Luxturna, gained FDA approval less than three years ago. The agency's experience with these types of treatment, therefore, is more limited than with other drug classes. The relative ease with which Luxturna, and then Novartis' Zolgensma, passed ...

www.wsj.com/articles/bayer-to-buy-gene-therapy-firm-askbio-for-up-to-4-billion...

The latest deal—for which Bayer will pay $2 billion now and as much as a further $2 billion based on future success milestones—is a bet on cutting-edge gene therapy, in which a functional gene ...

www.usnews.com/news/healthcare-of-tomorrow/articles/2019-04-10/commentary-gene...

The case of Jesse Gelsinger, an 18-year-old who died during a gene therapy experiment, comes to mind. Mr. Gelsinger had a disease called ornithine transcarbamylase deficiency, or OTC, which was ...

www.oaoa.com/news/business/gene-therapy-daily-news-service---researchand...

The "Gene Therapy Daily News" newsletter has been added to ResearchAndMarkets.com's offering. Gene Therapy Daily News is targeted towards scientific and medical researchers seeking the latest ...